Nasdaq

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine ...

DELRAY BEACH, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of ...
Business Insider

AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic ...

Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency (EPI). Patients in ...
Everyday Health

9 Tips for Traveling with EPI

You may think that the symptoms of exocrine pancreatic insufficiency (EPI) are hard enough to manage at home, let alone on the road. But with a little preparation, you can travel with confidence — and ...
Nasdaq

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe ...

DELRAY BEACH, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of ...